Journal of the American Chemical Society #GLP1 #Retatrutide #Obesity #MetabolicHealth #WeightLoss #HormoneTherapy #PrecisionMedicine #PersonalizedMedicine #Diabetes #ClinicalTrials #Biotech #Peptides Retatrutide: Triple-Agonist for Obesity and Metabolic Health I recently learned about retatrutide through an acquaintance a recreational weightlifter whos been selfadministering this investigational triple G peptide (mimicking GLP1, GIP, and glucagon)
In a January 2026 analysis, the most-engaged Noom GLP-1 Rx Program membersthose who use the Noom app most frequentlylost 25.2% more weight, on average, by week 40, than the least-engaged members (comparing the top and bottom quartiles based on engagement)
Clinical evidence from the STEP trials demonstrated that semaglutide users lost significantly more weight than those on placebo, with sustained results over 68 weeks
From the first week, I've felt a significant decrease in evening cravings, which have been a challenge for me
Exploring the Discrepancy Between Cell Culture and Animal Studies
What GPA do you need for an Eli Lilly internship
